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INTRODUCTION
THALIDOMIDE (a-PHTHALIMIDOPHTHALIMIDE) was f irst in-troduced in 1957 as a mild sedative–hypnotic and was
successfully distributed in several countries under numerous
trade names. The list of indications was expanded as addi-
tional therapeutic uses for the drug were discovered. A lack of
deleterious side effects, the inability to determine lethal con-
centrations, and the efficacy to relieve nausea associated with
pregnancy resulted in increased use by pregnant women.
Nearly 4 years after its introduction to the public, thalidomide
was found to be responsible for a broad spectrum of birth de-
fects, the most notable being limb reduction defects (pho-
comelia, amelia). The drug was subsequently removed from
the market because of the birth defects and manifestations of
an often irreversible peripheral neuropathy seen in adult pa-
tients who had taken thalidomide for longer periods of time
(17, 28, 52, 89). Although research was initially intense in at-
tempts to understand mechanisms of thalidomide-induced
limb dysmorphogenesis, no clear mechanisms were found,
and efforts waned due to thalidomide no longer being a threat
to public health. Interest in understanding the mechanism of
thalidomide-induced teratogenesis has been rekindled, how-
ever, because the drug was recently approved for sale and use
in Europe and South and North America. It is currently being
used as therapy for a variety of diseases, such as erythema no-
dosum leprosum, human immunodeficiency virus-related
wasting syndrome and esophageal ulcers, graft-versus-host
disease, arthritis, and tuberculosis and is being considered and
tested as a therapy for a number of other diseases (13, 56, 63).
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ABSTRACT
Several hypotheses have been proposed to explain the mechanisms of thalidomide teratogenesis, although
none adequately accounts for the observed malformations and explains the basis for species specificity. Recent
observations that thalidomide increases the production of free radicals and elicits oxidative stress, coupled
with new insights into the redox regulation of nuclear transcription factors, lead to the suggestion that
thalidomide may act through redox misregulation of the limb outgrowth pathways. Oxidative stress, as
marked by glutathione depletion/oxidation and a shift in intracellular redox potential toward the positive, oc-
curs preferentially in limbs of thalidomide-sensitive rabbits, but not in resistant rats. DNA binding of nuclear
factor k-B (NF-kB), a redox-sensitive transcription factor and key regulator of limb outgrowth, was shown to
be significantly attenuated in rabbit limb cells and could be restored following the addition of a free radical
spin-trapping agent, phenyl N-tert-butyl nitrone. The inability of NF-kB to bind to its DNA promoter results
in the failure of limb cells to express fibroblast growth factor (FGF)-10 and twist in the limb progress zone
(PZ) mesenchyme, which in turn attenuates expression of FGF-8 in the apical ectodermal ridge (AER). Fail-
ure to establish an FGF-10/FGF-8 feedback loop between the PZ and AER results in the truncation of limb
outgrowth. We hypothesize that species-selective alterations in redox microenvironment caused by free radi-
cal production from thalidomide results in attenuation of the NF-kB-mediated gene expression that is respon-
sible for limb outgrowth. Antioxid. Redox Signal. 6, 1–14.
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Reintroduction of thalidomide for general medicinal use re-
news the possibility of thalidomide-induced terata despite ef-
forts to regulate its application and to inform the public about
the potential dangers of misuse.
In all, >30 hypotheses have been proposed to explain
mechanisms of thalidomide teratogenesis. The significant hy-
potheses, presented to date, that are still under consideration
are summarized in Table 1. Many have focused on disruption
of biochemical and molecular pathways and include DNA in-
tercalation, acetylation of macromolecules, interference of glu-
tamate metabolism, and folic acid antagonism (5, 25, 40, 45,
79). Two recent hypotheses have suggested that thalidomide-
induced disruption of angiogenesis and the decreased expres-
sion of adhesion receptors are also possible teratogenic mech-
anisms (20, 62). Stephens and Fillmore (80) hypothesized
that thalidomide may interfere with the promoter of specific
genes [Igf-1 (insulin growth factor-1) and Fgf-2 (fibroblast
growth factor-2)] involved in limb outgrowth and develop-
ment, suggesting that thalidomide intercalates into DNA re-
gions that are guanine- and cytosine-rich, decreasing gene ex-
pression and resulting in limb truncation (83). Still, a paucity
of experimental evidence exists to either support or refute
many of these mechanisms. For some hypotheses, there has
been experimental support, but no single mechanism was elu-
cidated, and sufficient evidence is unavailable to adequately
explain thalidomide-induced limb reduction and account for
species specificity.
Here, we describe a novel molecular mechanism by which
thalidomide causes limb reduction defects.
Hypothesis: Thalidomide causes oxidative stress and a
change in intracellular redox potential in limb progress
zones where species-specific redox environments are not
intrinsically or rapidly restored to reducing conditions.
Oxidative redox potentials, particularly in the nucleus,
cause S-glutathionylation of nuclear factor-kB (NF-kB)
and prevent NF-kB binding to DNA. The subsequent NF-
kB-dependent gene expressions that are responsible for
maintaining limb outgrowth are attenuated, producing
phocomelia and amelia in affected offspring.
THALIDOMIDE INCREASES FREE
RADICAL PRODUCTION AND ELICITS
OXIDATIVE STRESS
Metabolic biotransformation of thalidomide has been at
the center of a long-standing debate surrounding the mecha-
nisms of thalidomide teratogenicity. Addition of thalidomide
to biological fluids results in the rapid, and presumably
nonenzymatic, hydrolysis to a number of ring-opened and
truncated products. The identity of the ultimate teratogenic
species, however, remains undetermined. Some of the biolog-
ical and therapeutic actions of thalidomide have now been
shown to require its metabolic biotransformation (8, 58). Re-
ports have provided evidence that prostaglandin H synthase
may be capable of bioactivating thalidomide (4), and new ev-
idence implicates a cytochrome P450 isozyme, CYP1A1, as
the bioactivator that produces decreases in fibroblast prolifer-
ation (58). Demonstration that an increased toxicity is seen
with the S-isomer of thalidomide suggests that at least one
macromolecular target is involved in its mechanistic interac-
tions (65, 66). It is not known whether the stereoselectivity is
related to a transport step, a signaling step, a biotransforma-
tion step, or any other interaction.
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TABLE 1. ACTIVE HYPOTHESES TO EXPLAIN THE MECHANISM OF THALIDOMIDE (1966–2003)
Hypothesis Authors Reference
Acylation of macromolecules Jonsson (1972) 40
Ascorbic acid synthesis Vaisman et al. (1983) 87
DNA intercalation Jonsson (1972) 40
Stephens and Fillmore (2000) 80
Disruption of angiogenesis Jurand (1966) 42
D’Amato et al. (1994) 20
Sauer et al. (2000) 74
Down-regulation of adhesion receptors Neubert et al. (1996) 62
Alteration of cytokine synthesis Sampaio et al. (1991) 73
(tumor necrosis factora)
Folic acid antagonism Kemper (1962) 45
Inhibition of DNA synthesis Bakay and Nyhan (1968) 5
DNA oxidation Parman et al. (1999) 68
Interference of glutamate metabolism Faigle et al. (1962) 25
Mesonephros-stimulated chondrogenesis Lash and Saxen (1971) 50
Lash and Saxen (1972) 51
Stephens and McNulty (1981) 81
Stephens and Pugmire (1986) 82
Oxidative stress Hansen et al. (1999) 32
Hansen et al. (2002) 33
Hansen et al. (2002) 34
Parman et al. (1999) 68
Sauer et al. (2000) 74
A significant breakthrough in our understanding of
thalidomide’s effects has come with the observation that
thalidomide acts as an oxidant and modulator of intracellular
redox potential. Sauer and co-workers (74) confirmed that
thalidomide forms hydroxyl radicals in murine embryonic
stem cells, a pluripotent cell line that can be induced to form
embryoid bodies, which differentiate to contain many differ-
ent cell types, including vascular structures. Thalidomide sig-
nificantly reduced angiogenesis in treated embryoid bodies,
which was correlated with the production of reactive oxygen
species (ROS). Addition of the free radical scavengers, 
2-mercaptoethanol and mannitol, completely abolished
thalidomide-induced antiangiogenic effects, further support-
ing a free radical-based mechanism for inhibition of angio-
genesis by thalidomide (74). A previous report by Bauer et al.
(8) provided evidence that metabolic bioactivation of thalido-
mide was necessary for its ability to inhibit angiogenesis.
They further showed that microsomes from sensitive species,
such as the rabbit and the human, are capable of activating
thalidomide to promote inhibition of angiogenesis, whereas
rat microsomes were ineffective.
Wells and co-workers (68) compared effects in two species,
thalidomide-sensitive rabbits and thalidomide-resistant mice,
in experiments designed to understand whether the species
differences seen in response to thalidomide could help eluci-
date possible teratogenic mechanisms. Rabbits were treated
with 400 mg/kg/day thalidomide and produced litters with
limb malformations (phocomelia) and other expected thalido-
mide-related defects (omphalocele). Thalidomide-exposed
fetuses had considerably higher concentrations of oxidized
DNA based on measurements of enhanced 8-hydroxy-29
-deoxyguanosine formation, a marker of oxidative stress, as
compared with control fetuses. In thalidomide-resistant mice,
litters showed no significant increases in limb malformation
or DNA oxidation, even with thalidomide doses as high as
1,600 mg/kg/day. These results suggest that rabbit, but not
mouse, fetuses accumulate damage due to oxidative stress,
and that there are inherent factors particular to the rabbit that
allow this to occur. Rabbits receiving thalidomide treatments
were also cotreated with a free radical spin-trapping agent, 
a-phenyl-N-tert-butylnitrone (PBN), to determine whether
the direct removal of free radicals prevented the observed
toxic outcome. PBN coadministration significantly decreased
limb malformations and, also, decreased DNA oxidation
compared with rabbit fetuses exposed to thalidomide only in
utero. Wells and co-workers suggest that thalidomide embry-
opathy involves free radical-mediated oxidative damage to
embryonic DNA (68).
By using a similar comparative approach, rat and rabbit
limb bud cells (LBCs) were collected at similar developmen-
tal stages (based on embryo somite number), grown in cul-
ture, and treated with thalidomide in vitro. The production of
ROS was determined using dichlorofluorescein (DCF), a dye
that produces a stable fluorescent product upon interaction
with hydrogen peroxide. Rat LBCs treated with 100 µM
thalidomide produced very little increase in DCF fluores-
cence (~40%), but rabbit LBCs treated with the same concen-
trations increased by nearly 200% from basal levels, approxi-
mately f ivefold greater than that seen in the rat. Treatment
with PBN attenuated thalidomide-induced ROS production in
both rat and rabbit LBCs as indicated by a return of DCF flu-
orescence to baseline levels (34). These results suggest that
thalidomide directly increases concentrations of ROS in cul-
tured limb cells and that the rabbit LBC is more apt to accu-
mulate ROS than is the rat LBC. Rat and rabbit LBCs also
showed evidence of ROS production following thalidomide
exposure based on the colocalization of redox-sensitive dyes
to mitochondria (34).
Although the above studies (34, 68, 74) implicate the gen-
eration of free radicals in thalidomide-induced limb terato-
genesis, they do not resolve the mechanism by which the free
radicals cause specific alterations of limb bud growth and de-
velopment. It has been suggested that an abundance of ROS
may create a permissive oxidative environment that allows for
signal transduction to be stimulated or inhibited, depending on
the initiating signal (75). The cellular response to ROS pro-
duction involves attempts to remove free radicals directly or
indirectly through the reduced glutathione (GSH)-dependent
detoxication pathways. As GSH is oxidized to glutathione
disulfide (GSSG) in the detoxication processes, ratios of
GSH/GSSG decrease, leading to a shift in the intracellular
redox potential. Redox potentials are calculated from mea-
sured concentrations of GSH and GSSG using the Nernst
equation (75). GSH is the most ubiquitous antioxidant, ac-
counting for nearly 90% of all intracellular reducing equiva-
lents found in cells (18) and is crucial in the maintenance of
intracellular redox potential (75). As redox potential is modu-
lated by ROS formation, a number of different cellular pro-
cesses related to metabolic regulation, signaling, and gene
expression can be inhibited or activated in response to oxida-
tive changes to the intracellular environment and may corre-
late with the promotion or inhibition of proliferation, differ-
entiation, and apoptosis (1–3, 9, 10, 12, 18, 36, 39, 46, 61, 77,
91). Maintenance of the proper redox potential may prove to
be even more critical during development as cell populations
are actively participating in proliferation, differentiation, and
apoptosis at various rates during critical periods of initial
growth. Chemically induced redox changes could promote
untimely activation or inhibition of developmental pathways,
resulting in faulty development and teratogenesis.
Initiation of conditions characterized as oxidative stress
occurs when increases in reactive species result in the net ox-
idation and depletion of GSH to a level where intracellular
redox potential is shifted to the positive and cellular damage
ensues. The ultimate manifestation of damage and duration
of altered redox potential is determined by the host’s inher-
ent ability to restore GSH redox status through disulfide re-
duction and de novo synthesis. Hansen and co-workers (32)
used two species with markedly different sensitivities to
thalidomide, the resistant Sprague–Dawley rat and sensitive
New Zealand White rabbit, to show that thalidomide expo-
sure in whole embryo culture results in a significantly
greater GSH depletion in the rabbit than in the rat conceptus
over a 24-h period. As GSH is the single largest contributor
to the intracellular pool of reducing equivalents (18), these
results confirm the preservation of a species sensitivity to
thalidomide in vitro and also implicate a deficiency in the
rabbit protective systems that results in a greater redox shift
than seen in the rat embryo under similar conditions of ox-
idative insult.
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Rat LBCs contain ~50% more GSH than rabbit LBCs (32),
suggesting a greater protective effect in the rat than the rabbit
LBC during periods of oxidative stress. To a greater extent,
similar species-specific trends were also evident with cys-
teine, which represents another important pool of reducing
equivalents and a critical rate-limiting precursor amino acid
required for de novo GSH synthesis. Rat LBC cysteine con-
centrations were nearly 3.5-fold greater than those in rabbit
LBCs, suggesting that the rat is more capable of handling a
higher oxidative load than the rabbit and is more capable of a
more complete restoration of GSH by de novo synthesis fol-
lowing depletion.
Additional comparisons of GSH status show that rat em-
bryos contain nearly 35% more GSH, a difference that con-
tributes to a +10 mV difference in redox potential between
the rabbit (2204 mV) and rat (2214 mV) embryos. Specific
redox differences within the limb followed similar trends,
with an +11 mV difference between untreated rabbit and rat
limbs, measuring 2164 mV in the rabbit limb and 2175 mV
in the rat limb. Findings indicate that the limbs of both
species are highly oxidative as compared with other embry-
onic tissues (i.e., trunk and head), the overall embryonic
redox potential is less negative (more oxidative) in the rabbit
than the rat, and the rabbit limb is much more oxidative than
the rat limb.
Another critical redox couple involved in the regulation of
several cellular pathways is the thioredoxin (Trx) and thiore-
doxin reductase redox couple. This enzyme pair has been
shown to be essential for the maintenance of a number of
active-site protein thiols (transcription factors) in their re-
duced and active states. Differences in limb Trx were signifi-
cant between the sensitive and resistant species, where the
rat limb had sixfold greater Trx concentrations than did the
rabbit limb. These differences were not seen in the other re-
gions of the embryo proper. Significant differences in Trx
could suggest at least three major regulatory and functional
implications for developmental outcome. First, Trx stimu-
lates and interacts with other antioxidant defense systems
(21) and can reactivate oxidized proteins following their de-
activation by hydrogen peroxide and other ROS exposures
(26). Second, Trx acts as an antioxidant itself, interacting di-
rectly with other disulfides to facilitate their reduction. Trx
can also interact directly with ROS, acting as a proton donor,
dimerizing and removing intracellular ROS in the process.
Third, Trx may be involved in protein–DNA interactions.
Many transcription factors are redox-sensitive in that they
contain sulfhydryls (cysteine residues) in their DNA binding
domains. These cysteine residues must be maintained in a re-
duced state in order for productive binding and subsequent
gene transactivation to occur (22, 29, 37). Because there is
inherently less Trx in the rabbit limb, the Trx-mediated
(de)activation of specific enzymes or transcription factors
may be inhibited or diminished to a greater degree than in
the rat limb.
We have measured inherent differences in limb redox po-
tentials, limb Trx, GSH, and cysteine concentrations between
the rat and rabbit, suggesting that the rat limb is less sensitive
to redox misregulation because it maintains a much more re-
ducing environment, higher Trx concentrations to regulate
Trx-mediated processes, and higher GSH and cysteine stores
to buffer redox potentials altered by ROS. Conversely, the
rabbit limb maintains a more oxidative environment, contains
less Trx, GSH, and cysteine, and is compromised in its ability
to detoxicate ROS and restore intracellular redox potentials
to a reducing range. These differences suggest that more
prolonged periods of potential misregulation and sustained
oxidative redox potential may occur during thalidomide-
induced teratogenesis in the rabbit, disrupting redox-sensitive
processes and subsequent downstream events.
NF-kB IS A REDOX SENSITIVE
TRANSCRIPTION FACTOR
NF-kB was first identified as a nuclear transcription factor
bound to the B-site of the immunoglobulin k enhancer in 
B-cells, but it was later determined to have similar binding
and gene transactivation activities in many other cell types
(6, 7). NF-kB is composed of two subunits, p50 and p65
(RelA), which combine to form a heterodimer in the func-
tional state of mammals such as the rat and rabbit. The p65
(RelA) subunit is regulatory and is bound to an inhibitory
protein, I-kB, while sequestered in an inactive state in the cy-
tosol (Fig. 1A). In order for NF-kB to be activated, I-kB is
phosphorylated, polyubiquinated, and degraded in the cell’s
proteosome. The free NF-kB can then translocate into the nu-
cleus, bind to relevant kB enhancer sites in DNA, and initiate
gene transcription (27). The p50 subunit accounts largely for
the interaction with the DNA binding through a novel DNA-
binding motif called a b barrel, consisting of a group of b
sheets (15, 30, 60). At the tip of the b barrel is the DNA bind-
ing loop that contains a critical cysteine residue, Cys62 (35).
The importance of Cys62 was confirmed by site-directed muta-
genesis where Cys62 substitution with alanine completely abol-
ished DNA-binding activities (54, 55). Preservation of Cys62 in
a reduced state is necessary for normal DNA binding to occur
(22, 27), which may rely largely on Trx reduction (30, 60). Ox-
idation of Cys62 results in a decreased DNA binding and the
subsequent loss of NF-kB-related gene expression (22, 27).
In NF-kB activation/binding studies, Molt-4 cells were ex-
posed to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a glu-
tathione reductase inhibitor that simultaneously increases
GSSG and decreases GSH in a dose-dependent manner. Con-
centrations of 100 µM BCNU caused a 250% increase in
GSSG from control while effectively depleting GSH concen-
trations by 50%, representing an oxidative redox potential
shift. Lower BCNU concentrations (3.3–10 µM) increased
NF-kB activation fourfold from control. However, upon addi-
tion of higher BCNU concentrations (30–100 µM), NF-kB
DNA binding decreased by eightfold from control (29).
Smaller shifts in redox status, as indicated by relatively low
concentrations of GSSG, are apparently not sufficient for NF-
kB and I-kB dissociation, but extraordinarily high concentra-
tions of GSSG, indicative of a much greater oxidative redox
shift, inhibit NF-kB/DNA binding. It has been proposed that
optimal NF-kB activity is achieved when intermediate GSSG
concentrations are encountered (29). If intracellular redox
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status is out of a moderately oxidative range, NF-kB may not
be able to functionally mediate signal transduction (Fig. 1B).
This distinction makes NF-kB a unique transcription factor in
that it reacts differently to fluctuations in redox status as com-
pared with other redox-sensitive transcription factors, such as
activator protein-1 (AP-1). As the intracellular environment
becomes increasingly oxidative, levels of AP-1 activation and
DNA binding increase. In contrast, in an oxidative environ-
ment, NF-kB activation increases, but DNA binding de-
creases (22). NF-kB is located in the cytosol and, following
activation, translocates to the nucleus. Therefore, NF-kB is
subject to redox microenvironments of both cellular compart-
ments, whereas AP-1 is located in the nucleus and is gener-
ally subject to that microenvironment only. As NF-kB can be
modulated by either, or both, redox environments, it has a
narrower functional range than other redox-sensitive tran-
scription factors.
MOLECULAR MECHANISMS OF LIMB
OUTGROWTH INVOLVE REDOX-
SENSITIVE REGULATORY PATHWAYS
Proliferation, differentiation, and apoptosis are all essen-
tial developmental events that require specific regulation
through control of gene expression to evoke the transition
from one cellular state to another. Genetic control of develop-
mental processes is largely regulated by the activities of tran-
scription factors. A number of transcription factors and cell
signaling elements associated with developmental gene ex-
pression have been shown to be subject to redox regulation in
other biological systems, but have not yet been systematically
evaluated for their role in developing systems. AP-1, p53,
NF-kB, and other transcription factors implicated in apopto-
sis, proliferation, and differentiation are dependent on normal
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FIG. 1. Activation, translocation, and DNA binding of NF-kB under normal reducing conditions and during oxidative
stress. In reducing conditions (A), NF-kB is bound to the inhibitory protein I-kB in an inactive form in the cytosol. Introduction
of an activating stimulus, including oxidative stress, initiates the phosphorylation of I-kB by I-kB kinase (IKK), resulting in dis-
sociation of the inhibitory subunit. Subsequent polyubiquitinization (UUU) facilitates proteolysis and destruction of the in-
hibitory subunit. The free NF-kB, with its reduced sulfhydryl (SH) in the binding domain, is free to translocate to the nucleus
where it binds to the kB motif of the promoter and initiates transcription of genes such as the limb growth factors. The enzyme
thioredoxin (TRX) is believed to maintain the critical DNA-binding sulfhydryl in its reduced form. In conditions of oxidative
stress (B), activation and removal of I-kB and subsequent translocation to the nucleus are likely to occur efficiently, but the criti-
cal DNA-binding sulfhydryl is subject to oxidation (S-glutathionylation) to NF-kB-S-SG and is unable to bind to the consensus
site in the promoter. Low levels of TRX would exacerbate this effect.
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FIG. 2. Proposed model for the NF-kB-mediated redox regulation of limb outgrowth in the PZ and in the AER under
normal conditions and during thalidomide-induced oxidative stress (10, 39). Limb outgrowth is maintained by NF-kB-
induced expression of growth regulators and transcription factors in the PZ, such as Twist, Msx-1, Lhx-2, and Fgf-10. TWIST is a
transcription factor that initiates expression of the FGFR-2 receptor. FGF-10 is a secretable growth factor that diffuses to the AER
and initiates expression of additional factors FGF-2, FGF-4, and FGF-8. The latter, in turn, diffuse back to the PZ to activate nu-
clear transcription factors that maintain expression of critical growth factors. As long as the PZ-AER signaling loop is maintained,
limb outgrowth continues unimpeded along the proximal–distal axis. Insults, such as thalidomide exposure, that increase ROS
production (as described in Fig. 1) result in the attenuation of NF-kB-mediated gene transactivation, preventing adequate growth
factor expression and disturbing the signaling loop required for proximal–distal limb outgrowth. As a result, limb growth is com-
promised and phocomelia or amelia result.
intracellular redox status for activation and/or DNA binding
and subsequent gene transactivation (77, 85).
NF-kB is the Drosophila analogue of Dorsal and is known
to play a critical specific role in the regulation of limb out-
growth and development (31). Developmental biologists have
long understood the essential relationship between the meso-
derm of the limb progress zone (PZ) and the apical ectoder-
mal ridge (AER) for productive limb outgrowth (53, 84).
Only recently have the underlying molecular signaling path-
ways been identified and partially characterized. Kanegae
and co-workers (43) utilized infection of chick embryos with
a nonreplicating adenovirus vector to overexpress two I-kB
mutants, I-kBM and I-kBDUb in attempts to examine the role
of NF-kB in the regulation of limb development. I-kBM con-
tains two alanine substitutions for serine-32 and serine-36,
the putative sites where I-kB must be initially phosphorylated
for NF-kB activation. Because I-kB phosphorylation cannot
occur, the NF-kB/I-kB complex does not dissociate and re-
mains sequestered and inactive in the cytosol. The I-kBDUb
mutant does not contain these same serine mutations and is
successfully phosphorylated, but the ubiquitination sites have
been selectively mutated to lysine residues, preventing ubiq-
uitination and subsequent I-kB degradation. Although NF-kB
dissociation from the inhibitory subunit initially occurs, 
I-kBDUb reassociates with NF-kB, rendering it inactive in
the cytosol before translocation to the nucleus can occur.
Limb buds transfected with either I-kB mutant inhibited
growth along the proximal–distal axis at the time of infection
and were noticeably malformed and reduced in size (43).
Bushdid and co-workers (11) used a slightly different I-kB
mutant (I-kBaDN), which lacks the f irst 40 amino acids that
contain the critical serine residues necessary for I-kB degra-
dation. Much like mutants used in the previous study by
Kanegae and co-workers (43), NF-kB is not able to dissociate
from I-kB and would remain sequestered in the inactive form
in the cytosol. In chick embryos infected prior to the estab-
lishment of the limb field, inactive NF-kB was sequestered in
the cytosol and produced a 70% incidence of the embryos
with morphological limb abnormalities, such as amelia, the
absence of limb bud outgrowth, and abnormal AER forma-
tion (11). The AER is a group of specialized cells located on
the distal portion of the limb bud responsible for proximodis-
tal development through interactions with the underlying
mesenchyme. Loss of AER signaling to the underlying mes-
enchyme via microdissection results in severe stunting of the
limb bud (84), illustrating the importance of the AER region
during limb development. Both sets of I-kB mutant experi-
ments produced a significant change in expression of mRNA
transcripts involved in the limb outgrowth feedback loop [in-
hibition of msx-1, twist, lhx-2, fgf-10, sonic hedgehog (shh),
fgf-8, fgf-2, and derepression of bone morphogenic protein-4
(BMP-4)].
The subset of genes, described above, that operate under
control of the redox-sensitive transcription factor NF-kB and
were found to be necessary for regulation of limb outgrowth
can be organized into the perspective of overall limb develop-
ment as shown in Fig. 2A. Induction of limb outgrowth along
the proximal–distal axis is initiated by growth factors se-
creted from somitic mesoderm, lateral plate mesoderm, and,
likely, the underlying mesonephros. Proximal–distal limb
outgrowth is controlled through reciprocal signaling between
the tissues of the lateral plate mesoderm and the overlying ep-
ithelium. Expression of Fgf-8 is detected early in the pre-
sumptive limb field prior to observable morphological
changes, and stimulates the proliferation of mesoderm and
organizes epithelial cells along the anterior–posterior axis to
become the AER (19). As the AER is organized, underlying
mesoderm begins to express NF-kB and Fgf-10 and is accom-
panied by an increase in mesenchymal cell proliferation.
Continued expression of Fgf-10 in the distal mesenchyme
(PZ) interacts with the AER through an epithelial Fgf recep-
tor isoform (Fgfr2, isoform IIIb) to serve as an “AER mainte-
nance factor” (53). Initiation of Fgf-10 expression is assumed
to be due to the activity of the transcription factor NF-kB, al-
though this issue has not been unequivocally resolved. As de-
scribed in the preceding section, inhibition of NF-kB results
in the alteration of expression of several genes in both the PZ
and the AER (Fig. 2B). It is not known whether these addi-
tional genes are directly responsive to NF-kB or whether their
regulation is indirect through NF-kB. Nonetheless, limb out-
growth proceeds when the PZ-AER transcription loop is in-
tact and msx-1, twist, lhx-2, fgf-10, shh, fgf-8, fgf-2, and
derepression of BMP-4 all occur in their spatial regions.
Mutations of the Twist gene, coding a basic helix–loop–
helix transcription factor, have been implicated in the
Saethre–Chotzen syndrome in humans where limb defects are
part of the observed spectrum of malformations (16, 24, 38,
69, 71). Loss of Twist activity seriously compromises limb
development because Twist is thought to regulate growth
through the expression of Fgfr-1 and Fgfr-2 (38, 78). Twist
expression usually occurs uniformly throughout the limb bud
mesenchyme, but infection with I-kB mutants produced a
marked reduction in the range of normal Twist expression.
Expression is selectively diminished in the distal mes-
enchyme of the limb PZ (11, 43). Evidence from I-kB mutant
infection studies suggests that NF-kB regulates expression of
Twist and that it is necessary for normal limb development
and outgrowth.
Infection with I-kB mutants also alters Fgf-8 expression in
the limb bud (Fig. 2B). Fgf-8 expression is normally re-
stricted exclusively to the AER where it is involved in a feed-
back loop with the underlying mesenchyme (PZ) and the
growth factor Fgf-10 (53, 67) via the interactions with Fgfr-
2b in the AER and Fgfr -2c in the PZ (90). Fgf-10 is a critical
factor during limb development as it contributes to limb bud
outgrowth through activation of Fgf-8 expression in the AER.
Transgenic mice, deficient in Fgf-10, fail to develop any
fore- or hindlimb elements and fail to express Fgf-8 in the
AER (44, 57). The Fgf-10/Fgf-8 feedback loop is what is
thought to be primarily responsible for limb bud outgrowth
and maintenance of the AER, but not directly involved in
limb bud patterning (53). Not only is Fgf-8 connected to the
initiation of limb bud development, but it is also related to the
maintenance of the expression of Shh in the zone of polariz-
ing activity (ZPA) (88) (Fig. 2). Shh is proposed to be the
principle mediator of the polarizing signaling activity along
the anterior–posterior axis as it can cause ZPA-like duplica-
tions when misexpressed in other portions of the limb bud
(14, 72, 88). I-kB mutant infection resulted in the loss of ex-
pression of both Fgf-8 and Shh in the AER and ZPA, respec-
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tively (43). Interestingly, the expression of genes involved
with limb patterning on axes of development, apart from
the proximal–distal, such as cHoxA10, cHoxA11, cHoxD9,
cHoxD10, and cHoxD13, were not affected by mutant I-kB
retroviral infection (11). These experiments did not investi-
gate the possible misregulation of other AER FGFs, such as
Fgf-2 or Fgf-4. Fgf-2 and Fgf-4 expression is also necessary
for limb bud outgrowth as past experiments have shown that
removal of the AER causes stunted growth of the limb bud,
but can be rescued with the addition of Fgf-2- and Fgf-4-
soaked beads (64, 84), suggesting some redundancy in limb
bud outgrowth pathways. Expression of BMP-4 was also
measured and showed an increase of expression (11). NF-kB
has been shown to repress the expression of BMP-4 in the
limb mesenchyme, thereby allowing for limb cell prolifera-
tion and outgrowth to occur before the formation of cartilage




An accurate hypothesis for the mechanism of thalidomide-
induced limb defects must not only explain the molecular re-
lationships between the exposure/environment and the ob-
served effects seen in vitro, but must also address species
specificity and be consistent with effects produced in the
whole animal. The multicompartment redox regulation of
NF-kB, as described above, would imply that both sensitive
and resistant species would activate NF-kB and facilitate its
translocation into the nucleus within the PZ, but that DNA
binding within the nucleus would be inhibited or attenuated
only in the sensitive species.
Misregulation of NF-kB activity alters the expression of
critical developmental genes in each regulatory region of the
limb bud, Twist and Fgf-10 in the PZ mesenchyme, Fgf-8 in
the AER, and Shh in the ZPA (11, 43). As NF-kB acts either
directly or indirectly to control the expression of limb bud de-
velopment genes in these areas, it is a prime target for redox
misregulation in thalidomide-induced limb teratogenesis.
Thalidomide produces oxidative stress (32, 34, 68, 74), and as
the redox potential of the cell shifts to a more oxidative envi-
ronment, NF-kB becomes more easily activated. Studies by
Hansen et al. (33) utilizing transient transfection of a green
fluorescent protein (GFP) reporter vector suggest that NF-kB
in the PZ of both rat and rabbit limb buds may be constitu-
tively active, due to the very positive redox potentials found in
these regions. Using DCF to localize the region of highest
ROS accumulation in the cell, thalidomide exposure in rabbit
LBCs caused the greatest area of fluorescence in the nucleus,
whereas thalidomide-treated rat LBCs showed no such local-
ization (34). These findings correlated with 5-chloromethyl-
fluorescein diacetate (CMFDA) staining for reduced GSH in
rat and rabbit LBCs (Fig. 3). GSH was depleted in the cytosol,
but nuclear concentrations were unaffected. Conversely, rabbit
LBCs, which do not contain as robust cytosolic GSH concen-
trations as the rat, showed depletion of both cytosolic and nu-
clear GSH with similar thalidomide treatments (34).
The preferential increase of nuclear ROS and loss of GSH
suggest that NF-kB misregulation most likely occurs in the
nuclear compartment rather than the cytosol and transpires at
the DNA binding level. Evaluation of NF-kB/DNA binding
efficiency following thalidomide exposure was determined in
both rat and rabbit LBCs using a GFP reporter vector.
Thalidomide caused a substantial decrease in GFP production
in rabbit LBCs, but rat LBCs were unaffected (33), indicating
rabbit susceptibility to thalidomide-induced misregulation
of NF-kB binding activity. DNA binding and subsequent
GFP production could be restored to control levels with
cotreatments of PBN or N-acetylcysteine and indicate that
thalidomide-induced NF-kB/DNA binding misregulation is
mediated by free radical formation or modulation of intracel-
lular redox potential (33).
Many of the preliminary studies implicating thalidomide
and oxidative stress in limb reduction defects have been per-
formed in vitro. However, estimation of thalidomide effects in
vivo is more difficult and offers many unique challenges. It is
very difficult to directly assess thalidomide-induced misregu-
lation of NF-kB binding as was demonstrated in vitro. To best
estimate the effects of thalidomide on NF-kB activities in
vivo, whole mount in situ hybridizations were performed on
genes that had previously been shown to be down-regulated
in the limb as a consequence of NF-kB misregulation (11, 43),
namely Twist, Shh, Fgf-10, and Fgf-8 in both rat and rabbit
embryos treated in utero (33).
Twist was shown to be unaffected with thalidomide treatment
in the gestational day (GD) 11 and 13 rat embryos and showed
expression in the mesenchyme underlying the AER, or the PZ
8 HANSEN AND HARRIS
FIG. 3. LBC stained with CMFDA for GSH localization.
Rat LBCs treated without (A) and with (B) 100 µM thalidomide
and rabbit LBCs treated without (C) and with (D) 100 µM
thalidomide for 120 min are presented. Nuclei are outlined
with a white dotted line. Cells were viewed by confocal mi-
croscopy. Thalidomide treatments in rat LBCs deplete cytosolic
GSH, but nuclear GSH remains. In rabbit LBCs, untreated cells
have less cytosolic GSH. Thalidomide treatment causes a com-
plete loss of GSH in both the cytosol and nucleus.
(Fig. 4). Following thalidomide treatment, rabbits of similar de-
velopmental age (GD 10–12) showed a complete loss of Twist
expression early in limb development (GD 10), but expression
was slowly restored in older embryonic limbs (GD 11–12) and
never reached levels comparable to those in untreated control
rabbit embryos (Fig. 5) (33). Although the loss of Twist expres-
sion would contribute to the disruption of the Fgf-8/Fgf-10
feedback loop and limb dysmorphogenesis, the effect of thalido-
mide on both Fgf-8 and Fgf-10 expression is equally as pro-
found. Fgf-8 expression in the AER is unaffected by thalido-
mide exposure in rat embryonic limbs (GD 11 and 13) (Fig. 4).
However, Fgf-8 expression in the rabbit AER is undetectable
with thalidomide treatment during the early stages of limb initi-
ation and development (GD 10), but increases as limb develop-
ment progresses (GD 11–12). Fgf-8 expression is localized to
the AER, but the restoration is seen only in limited regions of
the AER, not uniformly throughout the entire AER (Fig. 5) (33).
Recent studies where Shh was deleted in transgenic mice
showed that the loss of Shh expression also decreased the ex-
pression of Fgf-8, but the reduction of Fgf-8 expression only
occurred in the posterior portion of the limb, the area overlying
the ZPA, whereas the remainder of the AER was unaffected (49).
These same manifestations were evident in rabbit embryos
treated with thalidomide and, although not directly studied, sug-
gest that Shh is also affected (Fig. 2).
Finally, Fgf-10 expression was evaluated in the PZ. True to
form, rat embryos treated with thalidomide did not show any
significant decrease in Fgf-10 expression on either GD 11 or 13
(Fig. 4). Rabbit embryos treated with thalidomide showed
very little Fgf-10 expression on GD 10, but increased on sub-
sequent GDs. Interestingly, expression in treated rabbit em-
bryos is still very low at the very distal tip of the PZ, impli-
cating this region as a possible target for misregulation and
area of highest oxidative stress (Fig. 5) (33). Supporting this
idea, rat and rabbit limb buds treated with thalidomide in
utero were stained with mercury orange to determine the
GSH distribution. Although both rat and rabbit showed high
concentrations of GSH in the overlying AER with or without
thalidomide treatment, only the underlying PZ of the rabbit
was depleted of mercury orange staining, indicating that
the mesenchyme of the PZ is the region most affected by
thalidomide-induced oxidative stress (33).
The utility of implicating thalidomide-induced ROS pro-
duction in misregulation of limb outgrowth rests on the as-
sumption that elimination of ROS would also restore normal
signaling. As Parman and Wells (68) showed in the protection
against DNA oxidation, the use of a free radical spin trap
should reverse the deleterious effects of thalidomide in the
whole animal, including the misregulation of gene expression
in the rabbit as described above (33). Cotreatment of pregnant
rabbits with PBN (Fig. 5) did, in fact, prevent the loss of tran-
scriptional activity caused by thalidomide. This provides a
compelling argument in support of the hypothesis that
thalidomide selectively induces the production of ROS, re-
sulting in loss in DNA binding of NF-kB, reduction of gene
expression, and attenuation of limb outgrowth.
Although rabbit embryos treated with thalidomide showed
a temporary decrease of Fgf-10 expression (GD 10), restora-
tion of expression later in development corresponds to pre-
sented terata. Rabbit embryos rarely exhibit thalidomide-
induced amelia, but rather the primary limb reduction defect
is phocomelia. As the loss of Fgf-10 expression is transient,
limb bud development and outgrowth may simply be retarded
rather than inhibited and would yield limb reduction defects
such as phocomelia, not amelia.
PERSPECTIVES
The data presented in this editorial support the hypothesis
that thalidomide-induced limb defects involve ROS-mediated
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FIG. 4. In situ hybridization of GD 11 and GD 13 rat em-
bryos treated with thalidomide. White arrows point to re-
gions of expression of Fgf-10, Twist, and Fgf-8. Thalidomide
does not affect the expression of limb bud outgrowth gene
expression.
inhibition/attenuation of redox-sensitive transcription factors
in sensitive species. The fundamental mechanism by which
these effects are realized is believed to be the formation of a
GSH-protein mixed disulfide (S-glutathionylation) in the
critical DNA-binding domain (Cys62) of the p50 subunit of
NF-kB that prevents efficacious binding and gene transacti-
vation. S-Glutathionylation of cellular protein occurs exten-
sively when concentrations of GSSG increase during oxida-
tive stress, and the consequences are known to affect several
important cell functions (18, 48). This process has attracted
considerable recent attention due to demonstrations of impor-
tant regulatory roles in other systems (18, 47, 48). Pineda-
Molina et al. (70) suggest a complex scenario of regulation
through response to changes in the redox environment that
could involve several different modifications at the critical
DNA-binding cysteine in the transcription factor NF-kB that
could impart selective binding and reactivation characteris-
tics. Evidence is provided to support S-glutathionylation 
(-S-SG) and sulfenic acid (-SOH) formation in the reversible
inhibition of the transcription factor NF-kB when GSH/GSSG
ratios are shifted to produce a more oxidizing redox environ-
ment. In vitro experiments showed that GSH and GSSG con-
centrations of 1.0 and 0.1 mol of [3H] GSH/mg of protein, re-
spectively, result in a 40–70% inhibition of the binding of the
p50 wild-type subunit. Further reduction of the GSH/GSSG
ratios to 0.4 (GSH) and 0.1 mol (GSSG) of [3H]-GSH/mg of
protein caused complete inhibition of DNA binding. Depend-
ing on the magnitude of change in the intracellular redox po-
tentials and intrinsic cellular response capacities, a broad
spectrum of covalent modifications on the DNA-binding
cysteine may occur in NF-kB, ranging from reversible 
S-cysteinylation (-S-cys), S-glutathionylation (-S-SG), sul-
fenic acid formation (-SOH), and S-nitrosoglutathionylation
(GSNO) to the further extreme of irreversible oxidative modi-
fications such as sulfinic acid (-SO2H) and sulfonic acid 
(-SO3H). Reversibility of inhibition and restoration of DNA
binding are largely dependent on the availability of sufficient
GSH concentrations (reducing conditions) and enzymes, such
as Trx and other protein disulfide reductases, which can be
regulated in a cell-specific manner (23, 41, 47, 48). We pro-
pose that heterogeneity in the redox-inhibition states of NF-
kB may be cell- and tissue-specific and regulated, in part, by
selective abilities to respond to chemical and environmental
changes. An identical external stimulus may induce different
changes in intracellular redox status in order to stimulate pro-
liferation in one cell type through reversible inhibition and
differentiation or death in another due to the formation of irre-
versible thiol modifications. This phenomenon may have par-
ticular relevance to broader mechanisms in embryonic devel-
opment and stem cell biology where rapid changes in cell
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FIG. 5. In situ hybridization of GD 10 and GD 12 rabbit
embryos treated with thalidomide and co-treated with both
thalidomide and PBN. White arrows show regions of ex-
pected gene expression. Rabbit embryos treated with thalido-
mide showed a substantial decrease of Fgf-10, Twist, and Fgf-8
expression in specific regions of the developing limb. Cotreat-
ment with PBN blocked the deleterious effects of thalidomide
and restored normal expression patterns.
function, related to altered patterns of gene expression, are
often observed in the absence of any other obvious signals.
Although we have focused on NF-kB as the critical tran-
scription factor involved in the misregulation of limb out-
growth, we do not imply that other redox-sensitive transcrip-
tion factors and signal transduction elements are not also
significantly affected by variations in redox status. S-Gluta-
thionylation of the activator protein-1 (AP-1, c-jun) complex
has been shown to affect DNA binding in a manner similar to
that described for NF-kB (48). This system may not be di-
rectly involved in the cascade that regulates limb outgrowth,
but it may have particular relevance in the maintenance and
recovery of intracellular redox status following oxidative in-
sult. A good example is the AP-1-mediated induction of the
glutamate-cysteine ligase that is rate limiting for de novo
GSH synthesis and responsible for increasing GSH concen-
trations (86). Collectively, a number of redox-sensitive tran-
scription factors and signal transduction proteins (NF-kB,
AP-1, p53, SP-1, mitogen-activated protein kinase, c-Jun N-
terminal kinase, etc.) may be responsible for sensing the
redox-related changes elicited through environmental and
chemical insult to result in the inducible expression of genes
responsible for controlling important developmental pro-
cesses, such as proliferation, differentiation, and apoptosis
(2, 18, 39, 59, 77). This represents a novel level of gene regu-
lation during embryogenesis. “Environmental factors” that
contribute to cell signaling in early development could be
mediated through ROS and redox regulation in a manner that
has not been previously considered. Decreased gene expres-
sion in the developing limb due to the inhibition or attenua-
tion of redox-sensitive transcription factors provides a supe-
rior rationale for understanding mechanisms of other known
teratogens, which also increase the production of ROS. Due
to the dynamic nature of oxidative stress and the individual
cell’s dependence on pathways to restore normal reducing
conditions, cell and species sensitivity to teratogens may be
based on their antioxidant and response status. The intrinsic
ability of a cell or tissue to restore reducing conditions fol-
lowing an oxidative insult may determine whether misregula-
tion of redox-sensitive transcription factors occurs and pro-
motes dysmorphogenesis.
Thalidomide elicits a more positive, oxidized intracellular
redox potential, resulting in the misregulation of NF-kB. Dimin-
ished NF-kB binding to DNA in the limb PZ leads to loss or re-
duction of gene expression (Twist, Fgf-10, Fgf-8, and Shh), which
is critical for the continued proliferation and differentiation dur-
ing limb development, whereas other patterning genes, such as
the Hox genes, remain unaffected. These findings account for
thalidomide’s effect on limb reduction while still maintaining
normal patterning of the fingers and hand, mimicking the most
common human thalidomide-induced defect, phocomelia (76).
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ABBREVIATIONS
AER, apical ectodermal ridge; AP-1, activator protein-1;
BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; BMP-4, bone
morphogenic protein-4; CMFDA, 5-chloromethylfluorescein
diacetate; DCF, dichlorofluorescein; Fgf-2, f ibroblast growth
factor-2; Fgf-4, fibroblast growth factor-4; Fgf-8, fibroblast
growth factor-8; Fgf-10, fibroblast growth factor-10; Fgfr-1,
fibroblast growth factor receptor-1; Fgfr-2, fibroblast growth
factor receptor-2; GD, gestational day; GFP, green fluores-
cent protein; GSH, reduced glutathione; GSSG, glutathione
disulfide; Igf, insulin growth factor; LBC, limb bud cell; NF-
kB, nuclear factor-kB; PBN, a-phenyl-N-tert-butylnitrone;
PZ, progress zone; ROS, reactive oxygen species; Shh, sonic
hedgehog; Trx, thioredoxin; ZPA, zone of polarizing activity.
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